Fem-Dophilus

Fem-Dophilus contains two patented and clinically documented probiotic strains, Lactobacillus rhamnosus, GR-1® and Lactobacillus reuteri, RC-14®, discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech. Over 25 years of research supports the oral use of GR-1® and RC-14® to colonize and promote healthy vaginal and urinary tract health.* A special manufacturing process protects the probiotic strains in Fem-Dophilus® from stomach acid and enhances probiotic bacterial survival in the lower intestine.*

GR-1®/RC-14® and VAGINAL FLORA (also called microbiota) In one of the randomized clinical trials, 75% of women in the GR-1®/RC-14® probiotic group experienced significant improvement in vaginal flora composition, while only 34% of women in the placebo (non-probiotic) group experienced similar improvement.

Over 30 years of clinical research supports the effectiveness of the 2 patented probiotic bacterial strains in Fem-Dophilus®.* These beneficial strains populate the vaginal tract with healthy bacteria to balance the vaginal microbiome and help maintain a healthy vaginal and urinary tract.* These two strains are the most clinically published strains for vaginal health worldwide**, and were carefully selected due to their effectiveness in these studies.

Clinical Applications

• Fem-Dophilus® Function
• Oral Probiotic for Natural Vaginal/Urinary Tract Health*
• Fem-Dophilus® Highlights
• Clinically-Documented Benefits
• 25+ Years of Research and Clinical Studies For Vaginal and Urinary Tract Health*
• More Than 20 Studies Demonstrating Safety and Efficacy*
• Patented Lactobacilli Strains: GR-1® and RC-14®
• Prevention Magazine: Top 10 Breakthrough ’07

Suggested use